480 related articles for article (PubMed ID: 29122156)
1. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.
Murphy K; Jacobs J; Bjermer L; Fahrenholz JM; Shalit Y; Garin M; Zangrilli J; Castro M
J Allergy Clin Immunol Pract; 2017; 5(6):1572-1581.e3. PubMed ID: 29122156
[TBL] [Abstract][Full Text] [Related]
2. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
Brusselle G; Germinaro M; Weiss S; Zangrilli J
Pulm Pharmacol Ther; 2017 Apr; 43():39-45. PubMed ID: 28159511
[TBL] [Abstract][Full Text] [Related]
3. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
Máspero J
Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
[TBL] [Abstract][Full Text] [Related]
4. Reslizumab in Eosinophilic Asthma: A Review.
Deeks ED; Brusselle G
Drugs; 2017 May; 77(7):777-784. PubMed ID: 28421429
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
Lim HF; Nair P
Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
[TBL] [Abstract][Full Text] [Related]
6. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M; Zangrilli J; Wechsler ME; Bateman ED; Brusselle GG; Bardin P; Murphy K; Maspero JF; O'Brien C; Korn S
Lancet Respir Med; 2015 May; 3(5):355-66. PubMed ID: 25736990
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
9. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
[TBL] [Abstract][Full Text] [Related]
10. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
[TBL] [Abstract][Full Text] [Related]
11. Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials.
Virchow JC; Katial R; Brusselle GG; Shalit Y; Garin M; McDonald M; Castro M
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):540-548.e1. PubMed ID: 31404668
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis.
Li J; Wang F; Lin C; Du J; Xiao B; Du C; Sun J
J Asthma; 2017 Apr; 54(3):300-307. PubMed ID: 27435534
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma.
Carr WW; McDonald M; Meizlik P
Allergy Asthma Proc; 2019 Jul; 40(4):240-249. PubMed ID: 31262379
[No Abstract] [Full Text] [Related]
14. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
[TBL] [Abstract][Full Text] [Related]
15. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
Castro M; Mathur S; Hargreave F; Boulet LP; Xie F; Young J; Wilkins HJ; Henkel T; Nair P;
Am J Respir Crit Care Med; 2011 Nov; 184(10):1125-32. PubMed ID: 21852542
[TBL] [Abstract][Full Text] [Related]
16. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
17. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
[TBL] [Abstract][Full Text] [Related]
18. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
